 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 1234» |
- Preliminary analysis of treatment combinations in patients with amyotrophic lateral sclerosis enrolled in an US-based administrative claims database (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_625;
Patients with ALS continuously enrolled in Optum's de-identified ClinformaticsV R Data Mart (CDM) from 1 August 2017, through 30 September 2023, were included (intravenous) and Radicava ORSV and grouped based on ALS treatment combination... Patients were grouped based on use of riluzole only (n = 2193) vs. other FDA approved treatment/treatment combinations (n = 967) including Mitsubishi Tanabe Pharma America (MTPA) edaravone, PB-TURSO, riluzole
- Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Evolution of the treatment landscape for patients diagnosed with ALS in the United States (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_624;
Mitsubishi Tanabe Pharma America (MTPA) IV edaravone was introduced in 2017 and saw a consistent increase from 1 to 4.8% between 2017 and 2021. However, with the introduction of oral edaravone in 2022, the use of IV edaravone decreased to 1%, while the use of oral edaravone increased to 8.9%.
- Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Phase 3, open-label, safety extension study of oral edaravone (Radicava ORSV R ) administered over 96 weeks in patients with ALS (MT-1186-A03) (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_600;
P3
The most common treatment-emergent adverse events (TEAEs) were fall, muscular weakness, dyspnea, constipation, and dysphagia. These TEAEs were consistent with the safety profile for edaravone from previous clinical trials.
- Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Phase 3b study MT-1186-A02 to investigate the superiority of daily dosing vs the FDA-approved on/off regimen of oral edaravone (Radicava ORSV R )in patients with ALS (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_599;
P3b
Oral edaravone was well tolerated and no new safety concerns were identified in either group in Study MT-1186-A02. Daily oral edaravone did not show superiority to the FDA-approved on/off regimen in the CAFS, and was comparable in safety, efficacy, and tolerability to the on/off dosing regimen, therefore reinforcing the appropriateness of the FDA-approved regimen.
- Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Phase 3b Study MT-1186-A04 Extension Study to Evaluate the Continued Efficacy and Safety of Radicava ORSV R (Oral Edaravone) for up to an Additional 48-Weeks in Patients With Amyotrophic Lateral Sclerosis (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_598;
P3b
Oral edaravone was well tolerated and no new safety concerns were identified in either group in Study MT-1186-A04. Similar to the results obtained in MT-1186-A02, in MT-1186-A04, daily Radicava ORSV R did not show superiority to the FDA-approved on/off regimen (same safety, efficacy and tolerability profile) from the time of the randomization date in Study MT-1186-A02 to at least a 12-point decrease in ALSFRS-R or death, whichever happened first, and reinforces the appropriateness of the FDA-approved regimen.
- Radicava (edaravone) / Mitsubishi Tanabe
Treatment patterns and survival benefit of edaravone-treated people with ALS in the ALS/MND Natural History Consortium (517D) - Oct 1, 2024 - Abstract #ALSMND2024ALS_MND_19;
Radicava ORSV R (edaravone) oral suspension was FDA approved in 2022... Patients receiving edaravone
- Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Health care resource utilization of oral edaravone () - Apr 9, 2024 - Abstract #AMCP2024AMCP_109;
BACKGROUND: Intravenous (IV) edaravone (Radicava) was approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of amyotrophic lateral sclerosis (ALS) and was shown in clinical trials to slow the rate of physical functional decline. These real-world data may help clinicians and payers better understand the demographics, clini- cal characteristics, and HCRU of oral edaravone
- || edaravone oral (TTYP01) / Auzone Biological
Trial completion, Trial completion date: Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects (clinicaltrials.gov) - Mar 25, 2024
P1, N=29, Completed, Sponsor: Auzone Biological Technology Pty Ltd
These real-world data may help clinicians and payers better understand the demographics, clini- cal characteristics, and HCRU of oral edaravone Recruiting --> Completed | Trial completion date: May 2024 --> Dec 2023
- Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
A Preliminary Analysis of Oral Edaravone-Treated Patients With Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_400;
Recruiting --> Completed | Trial completion date: May 2024 --> Dec 2023 OBJECTIVES: Intravenous (IV) edaravone (Radicava
- Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
A Preliminary Analysis of Oral Edaravone-treated Patients with Amyotrophic Lateral Sclerosis Enrolled in a US-based Administrative Claims Database (Colorado Convention Center | Four Seasons 2/3) - Mar 8, 2024 - Abstract #AAN2024AAN_2358;
OBJECTIVES: Intravenous (IV) edaravone (Radicava Background:Intravenous (IV) edaravone (Radicava
- Radicava (edaravone) / Mitsubishi Tanabe
Interim Analysis of the Radicava/ Edaravone Findings in Biomarkers from ALS (REFINE-ALS) Study (Event Halle, Messe Basel, Ground Floor) - Nov 7, 2023 - Abstract #ALSMND2023ALS_MND_457;
Biomarker and clinical data from this interim analysis will be presented. Results from this ongoing study may help to identify prognostic and disease monitoring markers of ALS and predictive and pharmacodynamic biomarkers of edaravone effect.
- Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
A Preliminary Analysis of Oral Edaravone-Treated Patients With Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database (Event Halle, Messe Basel, Ground Floor) - Nov 7, 2023 - Abstract #ALSMND2023ALS_MND_304;
Oral edaravone-treated patients with ALS (n = 231) consisted of 59 patients in Group 1 and 172 patients in Group 2. Group 1 and Group 2 were predominantly male (59.3 and 58.7%), White (72.9 and 77.3%), from the southern US (39.0 and 40.1%), and covered by Medicare (69.5% and 59.3%), with a mean
- ||||||||| Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Trial termination: Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS (clinicaltrials.gov) - Oct 30, 2023
P3b, N=384, Terminated, Sponsor: Mitsubishi Tanabe Pharma America Inc.
Group 1 and Group 2 were predominantly male (59.3 and 58.7%), White (72.9 and 77.3%), from the southern US (39.0 and 40.1%), and covered by Medicare (69.5% and 59.3%), with a mean Active, not recruiting --> Terminated; Futility was met.
- | Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS (clinicaltrials.gov) - Oct 30, 2023
P3b, N=202, Terminated, Sponsor: Mitsubishi Tanabe Pharma America Inc.
Active, not recruiting --> Terminated; Futility was met. N=300 --> 202 | Trial completion date: Jun 2024 --> Sep 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Sep 2023; Futility Analysis of parent study MT-1186-A02 was met.
- || edaravone oral (TTYP01) / Auzone Biological
New P1 trial: Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects (clinicaltrials.gov) - Oct 29, 2023
P1, N=30, Recruiting, Sponsor: Auzone Biological Technology Pty Ltd
- ||||| Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Trial completion: Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Oct 27, 2023
P3, N=124, Completed, Sponsor: Mitsubishi Tanabe Pharma America Inc.
N=300 --> 202 | Trial completion date: Jun 2024 --> Sep 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Sep 2023; Futility Analysis of parent study MT-1186-A02 was met. Active, not recruiting --> Completed
- ||||| Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Trial completion, Enrollment change: Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS (clinicaltrials.gov) - Oct 27, 2023
P3, N=15, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Active, not recruiting --> Completed Recruiting --> Completed | N=30 --> 15
- || Radicava (edaravone) / Mitsubishi Tanabe
Biomarker, Enrollment closed, Trial completion date, Trial primary completion date: Radicava (clinicaltrials.gov) - Aug 24, 2023
P=N/A, N=300, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma America Inc.
Recruiting --> Completed | N=30 --> 15 Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
- Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2487;
P3
Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024 Background An intravenous (IV) formulation of edaravone (Radicava
- ||||| Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Enrollment closed: Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS (clinicaltrials.gov) - Feb 15, 2023
P3b, N=380, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
Background An intravenous (IV) formulation of edaravone (Radicava Recruiting --> Active, not recruiting
- | Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Journal: Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. (Pubmed Central) - Dec 13, 2022
Recruiting --> Active, not recruiting This study indicated that oral edaravone was well tolerated during 48 weeks of treatment, with no new safety concerns identified.
- | Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Enrollment status: Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS (clinicaltrials.gov) - Nov 28, 2022
P3, N=30, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
This study indicated that oral edaravone was well tolerated during 48 weeks of treatment, with no new safety concerns identified. Enrolling by invitation --> Recruiting
- || Radicava (edaravone) / Mitsubishi Tanabe
PK/PD data, Journal: Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants. (Pubmed Central) - Nov 17, 2022
P1
Oral administration of edaravone with a meal decreased the plasma concentration of edaravone. Oral administration of edaravone 8 hours after a high-fat meal, 4 hours after a low-fat meal, 2 hours after a light meal, and 1 hour before a high-fat meal showed no effect of food on the PK profile of unchanged edaravone compared with that observed under a fasted condition.
- || Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Enrollment open: Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS (clinicaltrials.gov) - Nov 16, 2022
P3, N=30, Enrolling by invitation, Sponsor: Mitsubishi Tanabe Pharma Corporation
Oral administration of edaravone 8 hours after a high-fat meal, 4 hours after a low-fat meal, 2 hours after a light meal, and 1 hour before a high-fat meal showed no effect of food on the PK profile of unchanged edaravone compared with that observed under a fasted condition. Not yet recruiting --> Enrolling by invitation
- Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Phase 3b, Multicenter, Randomized, DoubleBlind, Parallel-Group Study Evaluating Efficacy and Safety of Investigational Oral Edaravone Administered over 48 Weeks in Patients with Amyotrophic Lateral Sclerosis () - Oct 17, 2022 - Abstract #ANA2022ANA_608;
Background : An IV formulation of edaravone (Radicava®/ Radicut) was shown to slow the rate of physical functional decline in ALS. This study will provide important information on the safety, efficacy, and tolerability of two dosing regimens for oral edaravone in patients with ALS.
- Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Phase 3, Open-Label, Safety Extension Study of Investigational Oral Edaravone Administered over 96 Weeks in Patients with ALS (MT-1186-A03) () - Oct 17, 2022 - Abstract #ANA2022ANA_607;
Background : Radicava® (edaravone injection) is a US FDAapproved treatment for amyotrophic lateral sclerosis (ALS), shown to slow the rate of physical functional decline. This extension study will provide important information on the continued long-term safety and tolerability of this investigational oral formulation of edaravone in patients with ALS.
- Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients with Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results () - Oct 17, 2022 - Abstract #ANA2022ANA_606;
Background : An intravenous (IV) formulation of edaravone (Radicava®/Radicut) has been shown to slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS). This study demonstrates that oral edaravone was generally safe and well tolerated during 48 weeks of treatment, with no new safety concerns identified.
- || Radicava (edaravone) / Mitsubishi Tanabe
P1 data, Journal: Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study. (Pubmed Central) - Oct 14, 2022
No serious adverse events or adverse drug reactions were reported. These results suggest that oral edaravone suspension can be administered directly to the stomach without dose adjustment via feeding tubes; both oral and NGT administration are well tolerated.
- |||| Radicava ORS (edaravone oral) / Mitsubishi Tanabe
New P3 trial: Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS (clinicaltrials.gov) - Oct 5, 2022
P3, N=30, Not yet recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- | Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Journal: In brief: Edaravone oral suspension (Radicava ORS) for ALS. (Pubmed Central) - Sep 20, 2022
These results suggest that oral edaravone suspension can be administered directly to the stomach without dose adjustment via feeding tubes; both oral and NGT administration are well tolerated. No abstract available
- | Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Journal: New Oral Form for ALS Drug. (Pubmed Central) - Sep 2, 2022
The Food and Drug Administration has approved an oral suspension form of edaravone (Radicava ORS) for the treatment of amyotrophic lateral sclerosis.Edaravone should be taken on an empty stomach in the morning either by mouth or through a feeding tube. Feeding tubes should be flushed before and after drug administration.
- |||| Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Enrollment closed: Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - May 13, 2022
P3, N=140, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
Feeding tubes should be flushed before and after drug administration. Recruiting --> Active, not recruiting
- || Radicava ORS (edaravone oral) / Mitsubishi Tanabe
New P1 trial: Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study) (clinicaltrials.gov) - Apr 21, 2022
P1, N=16, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
- Radicava (edaravone) / Mitsubishi Tanabe, Oral Radicava (edaravone oral) / Mitsubishi Tanabe
Study Design for a Phase 3, Multicenter, Open-Label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Patients with ALS (MT-1186-A03) (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3507;
Background: Radicava® (edaravone injection) is a US Food and Drug Administration–approved treatment for ALS that slows the rate of physical functional decline. This extension study of oral edaravone will provide important information on the continued long-term safety and tolerability of this new formulation of edaravone in patients with ALS.
- Radicava (edaravone) / Mitsubishi Tanabe, Oral Radicava (edaravone oral) / Mitsubishi Tanabe
24-Week Results From Phase 3 Study MT-1186-A01 an Open-Label, Multicenter Safety Study of Oral Edaravone in Subjects With Amyotrophic Lateral Sclerosis (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2514;
Background: Radicava® (edaravone) is a US Food and Drug Administration–approved treatment for ALS that has been shown to slow the rate of physical functional decline. The first phase 3 trial of oral edaravone provided important information on the long-term safety and tolerability of this new formulation of edaravone in patients with ALS.
- || Radicava (edaravone) / Mitsubishi Tanabe
Clinical, PK/PD data, Journal: Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. (Pubmed Central) - Feb 23, 2022
Study 2 was conducted in 2 cohorts (n = 84); the first assessed DDIs with multiple-dose edaravone 120 mg/day given over 5 or 8 days (coadministered with single-dose rosuvastatin, sildenafil, or furosemide), and the second evaluated PK and racial (Japanese/White) differences in PK parameters with doses of 100-mg edaravone...The oral edaravone formulations were safe and tolerable under the assessed conditions. Mathematical modeling determined that equivalent exposures in plasma with the approved dose of the IV edaravone formulation, as reported previously, could be achieved when the oral edaravone formulation was administered at a dose of ≈100 mg, with an absolute bioavailability of ≈60%.
- |||| Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Trial completion date, Trial primary completion date: Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS (clinicaltrials.gov) - Feb 21, 2022
P3b, N=380, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
Mathematical modeling determined that equivalent exposures in plasma with the approved dose of the IV edaravone formulation, as reported previously, could be achieved when the oral edaravone formulation was administered at a dose of ≈100 mg, with an absolute bioavailability of ≈60%. Trial completion date: Mar 2022 --> Jul 2023 | Trial primary completion date: Mar 2022 --> Jul 2023
- |||||| Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Enrollment open: Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS (clinicaltrials.gov) - Feb 9, 2022
P3b, N=300, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
Trial completion date: Mar 2022 --> Jul 2023 | Trial primary completion date: Mar 2022 --> Jul 2023 Not yet recruiting --> Recruiting
- || Radicava (edaravone) / Mitsubishi Tanabe
Biomarker, Trial completion date, Trial primary completion date: Radicava (clinicaltrials.gov) - Dec 21, 2021
P=N/A, N=300, Recruiting, Sponsor: Mitsubishi Tanabe Pharma America Inc.
Not yet recruiting --> Recruiting Trial completion date: Feb 2022 --> Mar 2023 | Trial primary completion date: Feb 2022 --> Mar 2023
- |||||||||| Radicava ORS (edaravone oral) / Mitsubishi Tanabe
New P3 trial: Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS (clinicaltrials.gov) - Dec 9, 2021
P3b, N=300, Not yet recruiting, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
- ||||| Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Trial completion: Safety Study of Oral Edaravone Administered in Subjects With ALS (clinicaltrials.gov) - Nov 8, 2021
P3, N=185, Completed, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
Trial completion date: Feb 2022 --> Mar 2023 | Trial primary completion date: Feb 2022 --> Mar 2023 Active, not recruiting --> Completed
- Radicava (edaravone) / Mitsubishi Tanabe, Oral Radicava (edaravone oral) / Mitsubishi Tanabe
[VIRTUAL] Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone Administered Over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis: Study Design and Baseline Characteristics (MT-1186-A01) () - Oct 21, 2021 - Abstract #ANA2021ANA_461;
Additional baseline characteristics will be included in the late-breaking presentation. The first phase 3 trial of oral edaravone will provide important information on the long-term safety and tolerability of this new formulation of edaravone in patients with ALS.
- || Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Trial completion: Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube (clinicaltrials.gov) - May 12, 2021
P1, N=36, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
The first phase 3 trial of oral edaravone will provide important information on the long-term safety and tolerability of this new formulation of edaravone in patients with ALS. Active, not recruiting --> Completed
- || Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Enrollment closed: Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube (clinicaltrials.gov) - Mar 21, 2021
P1, N=36, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Radicava ORS (edaravone oral) / Mitsubishi Tanabe
New P1 trial: Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube (clinicaltrials.gov) - Feb 28, 2021
P1, N=36, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- | edaravone (MT-1186) / Mitsubishi Tanabe
Preclinical, Journal, IO Biomarker: Edaravone Ameliorates Renal Warm Ischemia-Reperfusion Injury by Downregulating Endoplasmic Reticulum Stress in a Rat Resuscitation Model. (Pubmed Central) - Dec 23, 2020
In conclusion, we found that EDR ameliorates renal warm IRI by downregulating ERS and its downstream effectors in a rat AKI model evoked by CA/CPR. These data may provide evidence for future therapeutic benefits of EDR against AKI induced by CA/CPR.
- | DexIron (iron dextran) / Daiichi Sankyo, edaravone (MT-1186) / Mitsubishi Tanabe
Journal: Tetramethylpyrazine alleviates iron overload damage in vascular endothelium via upregulating DDAHII expression. (Pubmed Central) - Dec 23, 2020
The effects of TMP against iron overload were similar to the positive control groups, L-arginine, a competitive substrate of ADMA, or edaravone, free radical scavenger. These results signify that TMP alleviated iron overload damage in vascular endothelium via ROS/ADMA/ DDAHII/eNOS/NO pathway.
- || Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Clinical, Journal: Effects of edaravone on postoperative cognitive function in elderly patients undergoing hip joint replacement surgery: A randomized controlled trial. (Pubmed Central) - Dec 23, 2020
These results signify that TMP alleviated iron overload damage in vascular endothelium via ROS/ADMA/ DDAHII/eNOS/NO pathway. The results indicated that preoperative intervention with edaravone may improve the postoperative cognitive function in elderly patients undergoing hip joint replacement surgery.
- | edaravone (MT-1186) / Mitsubishi Tanabe
Journal: Oxidative stress evaluation of skeletal muscle in ischemia-reperfusion injury using enhanced magnetic resonance imaging. (Pubmed Central) - Dec 18, 2020
Furthermore, the effect of edaravone (radical scavenger) was evaluated in the 4-h ischemia-24-h reperfusion injury rat model...The signal intensity of the ischemia-reperfusion limb was stronger than that of the intact limb, presumably reflecting the oxidative stress in the former. 3-CP MRI examination shows promise for effective assessment of oxidative stress and may facilitate early diagnosis of ischemia-reperfusion injury.
- | ebselen (SPI-3005) / Sound Pharma, edaravone (MT-1186) / Mitsubishi Tanabe
Journal: Reaction targets of antioxidants in azo-initiator or lipid hydroperoxide induced lipid peroxidation. (Pubmed Central) - Dec 16, 2020
In contrast, ebselen and ferrostatin-1 showed strong antioxidative activity in the HpODE/hemin-induced peroxidation...In conclusion, we found that each antioxidant had different antioxidative activities that prevented the progression of LPO. We expect that these findings will contribute to the design of novel therapeutic strategies using an appropriate antioxidant targeted to each step of the development of oxidative stress diseases.